DR. LEWIS C. CANTLEY

Co-Founder, Agios Pharmaceuticals (NASDAQ: AGIO); Co-Founder, Petra Pharma; Professor of Cancer Biology in Medicine, Weill Cornell Medicine; Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine/Ronald P. Stanton Clinical Cancer Program at New York-Presbyterian

Lewis Cantley has made significant advances in cancer research, stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. His pioneering research has resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases. The author of over 400 original papers and more than 50 book chapters and review articles, Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He graduated summa cum laude with a B.S. in chemistry from West Virginia Wesleyan College (1971) and obtained a Ph.D. in biophysical chemistry from Cornell University (1975). He conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978. He became a professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992. He became chief of Harvard’s new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002. In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and NewYork-Presbyterian Hospital in 2012.

Dr. Juan R. Cubillos-Ruiz

Juan R. Cubillos-Ruiz, PhD, Assistant Professor of Microbiology & Immunology in Obstetrics and Gynecology; Instructor of Microbiology and Immunology in Medicine, Weill Cornell MedicineText Block #5

Juan R. Cubillos-Ruiz, PhD, is an Assistant Professor of Immunology at Weill Cornell Medicine. He obtained a Ph.D. in Cancer Immunology from Dartmouth Medical School and then pursued his postdoctoral training at Harvard and Weill Cornell in the laboratory of Dr. Laurie Glimcher. He has 11 years of research experience in the immuno-oncology field. His laboratory combines cancer biology, immunology, molecular genetics and nanotechnology to identify, understand and disable the mechanisms that tumors use to manipulate the immune system. The main goal of his team is to devise more effective immunotherapies for lethal malignancies.  Cubillos-Ruiz recently received the Daedalus Award for Innovation, the Ovarian Cancer Academy-Early Career Investigator Award of the Department of Defense, and the Stand Up to Cancer Innovative Research Grant. Cubillos-Ruiz is also Co-Founder of Quentis Therapeutics, a New York City-based Startup Company focused on developing the next generation of cancer immunotherapies.